PerkinElmer and Procognia to Offer Breakthrough Protein Array Platform.MAIDENHEAD Maidenhead, city (1991 pop. 59,809), Windsor and Maidenhead, S central England, on the Thames River. It is a residential town with brewing and milling industries as well as a resort. The 13th-century stone bridge was rebuilt in the 1770s. , England & BOSTON -- --Complete Solution for Glycosylation of Proteins --Very Rapid Throughput Time --Worldwide Marketing and Distribution Agreement PerkinElmer, Inc. (NYSE NYSE See: New York Stock Exchange : PKI (Public Key Infrastructure) A framework for creating a secure method for exchanging information based on public key cryptography. The foundation of a PKI is the certificate authority (CA), which issues digital certificates that authenticate the identity of ), a global leader in health sciences, and Procognia, a leading developer of innovative and transformational technologies in the field of proteomics, today announced an exclusive distribution and co-marketing agreement to deliver the only complete solution for high-throughput and high-resolution analysis of the glycosylation of proteins. Procognia's U-c fingerprint lectin lectin /lec·tin/ (lek´tin) any of a group of hemagglutinating proteins found primarily in plant seeds, which bind specifically to the branching sugar molecules of glycoproteins and glycolipids on the surface of cells. array-based platform is being combined with PerkinElmer's advanced instrumentation, the Protein Array Workstation(TM) and the recently introduced ProScanArray(TM) HT, to offer the industry's first high-throughput, high-resolution glycoanalysis capability. Certain scientific estimates indicate that more than 60% of critical biological functions involve glycosylated proteins. This new technology will drive significant advancements in the understanding of protein function and structure. U-c fingerprint technology requires no sample purification or pretreatment pretreatment, n the protocols required before beginning therapy, usually of a diagnostic nature; before treatment. pretreatment estimate, n See predetermination. , and allows the quantitative analysis Quantitative Analysis A security analysis that uses financial information derived from company annual reports and income statements to evaluate an investment decision. Notes: of 20 samples in approximately three hours. In addition, glycosylation analysis throughout the therapeutic protein discovery, development and manufacturing process will bring biopharmaceutical companies closer to satisfying the FDA's PAT (Process Analytical Technology Process Analytical Technology (PAT) has been defined by the United States Food and Drug Administration (FDA) as a mechanism to design, analyze, and control pharmaceutical manufacturing processes through the measurement of critical process parameters and quality attributes. ) initiative. This technology is focused on reducing the time and cost of producing higher quality biopharmaceuticals. "Procognia is a leader in proteomic technologies and together with PerkinElmer's extensive capabilities, we can now offer the industry's first complete high-throughput, high-resolution glycoanalysis platform for academic, biotech, and pharmaceutical customers," said Peter Coggins, PhD., president, PerkinElmer Life and Analytical Sciences. "We believe we can accelerate adoption of Procognia's U-c fingerprint technology and firmly establish it as the gold standard in the monitoring and control of glycosylation of proteins by teaming with a global life sciences solutions provider like PerkinElmer," said Ron Long, CEO (1) (Chief Executive Officer) The highest individual in command of an organization. Typically the president of the company, the CEO reports to the Chairman of the Board. of Procognia Ltd. Factors Affecting Future Performance This press release contains "forward-looking" statements within the meaning of the Private Securities Litigation Reform Act The Private Securities Litigation Reform Act of 1995 (PSLRA) implemented several significant substantive changes affecting certain cases brought under the federal securities laws, including changes related to pleading, discovery, liability, class representation and awards fees and of 1995. Any statements contained in this press release that relate to prospective events or developments are deemed to be forward-looking statements. Words such as "believes," "anticipates," "plans," "expects," "projects," "forecasts," "will" and similar expressions are intended to identify forward-looking statements. There are a number of important risk factors that could cause actual results or events to differ materially from those indicated by these forward-looking statements, including risks related to cyclical downturns affecting several of the industries into which we sell our products, our failure to introduce new products in a timely manner, the impact of our debt on our cash flow and investment opportunities, our ability to comply with financial covenants contained in our credit agreements and debt instruments, risks related to our international operations Internal Operations (I.O., IO or I/O) is a fictional American Intelligence Agency in Wildstorm comics. It was originally called International Operations. I.O. first appeared in WildC.A.T.S. volume 1 #1 (August, 1992) and was created by Brandon Choi and Jim Lee. , our ability to adjust our operations to address unexpected changes, our ability to execute acquisitions and license technologies and successfully integrate acquired businesses and licensed technologies into our existing business, the loss of any of our licenses that may require us to stop selling products or lose competitive advantage, competition, regulatory changes, our failure to obtain and enforce intellectual property protection, our defense of third party claims of patent infringement patent infringement n. the manufacture and/or use of an invention or improvement for which someone else owns a patent issued by the government, without obtaining permission of the owner of the patent by contract, license or waiver. and our ability to realize the full value of our intangible assets, as well as other factors which we describe under the caption "Forward-Looking Information and Factors Affecting Future Performance" in our most recently filed annual report on Form 10-K Form 10-K A report required by the SEC from exchange-listed companies that provides for annual disclosure of certain financial information. Form 10-K See 10-K. and in our most recently filed quarterly report on Form 10-Q Form 10-Q See 10-Q. . We disclaim any intention or obligation to update any forward-looking statements as a result of developments occurring after the date of this press release. About PerkinElmer PerkinElmer, Inc. is a global technology leader focused in the following businesses - Life and Analytical Sciences, Optoelectronics and Fluid Sciences. Combining operational excellence and technology expertise with an intimate understanding of our customers' needs, PerkinElmer provides products and services in health sciences and other advanced technology markets that require innovation, precision and reliability. The Company serves customers in more than 125 countries, and is a component of the S&P 500 Index. Additional information is available through www.perkinelmer.com or 1-877-PKI-NYSE. About Procognia Procognia, a 2004 World Economic Forum Technology Pioneer award winner, is focused on developing and commercializing its cutting edge proprietary technologies that will enable the unraveling of disease mechanisms and the discovery and development of drugs to treat those diseases. In addition to developing the glycoanalysis platform, Procognia has developed arrays of biologically related proteins that retain their physiological function in the array format. Procognia was formed in April 2002 with a corporate headquarters and manufacturing in Maidenhead, United Kingdom. Commercial operations are run from the United Kingdom and Exton, PA, United States United States, officially United States of America, republic (2005 est. pop. 295,734,000), 3,539,227 sq mi (9,166,598 sq km), North America. The United States is the world's third largest country in population and the fourth largest country in area. , and supported by R&D facilities in Maidenhead, United Kingdom and Ashdod, Israel. Additional information available at www.procognia.com. |
|
||||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion